FDA OKs T-DXd Companion Diagnostic in HER2-Low Metastatic Breast Cancer
The FDA has granted approval to the PATHWAY HER2 test as a companion diagnostic to identify patients with hormone receptor (HR)–positive, HER2-ultralow metastatic breast cancer eligible for fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd), according to a …